Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
About this item
Full title
Author / Creator
Publisher
New Zealand: Dove Medical Press Limited
Journal title
Language
English
Formats
Publication information
Publisher
New Zealand: Dove Medical Press Limited
Subjects
More information
Scope and Contents
Contents
The new-generation hormonal agent enzalutamide has been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC), in both post- and predocetaxel setting, due to the significant improvement in overall survival. More recently, enzalutamide also showed impressive results in the treatment of men with nonmetastatic CRPC. Unfo...
Alternative Titles
Full title
Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6204864
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6204864
Other Identifiers
ISSN
1178-6930
E-ISSN
1178-6930
DOI
10.2147/OTT.S153764
